Table 2 Medication summary
From: Genetic and phenotypic characterization of Parkinson’s disease at the clinic-wide level
Whole Cohort | Male | Female | GBA1/LRRK2 Negative | GBA1 Carrier | LRRK2 Carrier | |
|---|---|---|---|---|---|---|
N (%) | 1674a | 1070 | 604 | 1469 | 158b | 44b |
None | 104 (6) | 53 (5) | 51 (8) | 88 (5) | 15 (1) | 1 (<1) |
Levodopa | 1455 (87) | 944 (88) | 511 (85) | 1281 (87) | 134 (85) | 38 (86) |
DA agonist | 356 (21) | 219 (21) | 137 (23) | 310 (21) | 28 (18) | 17 (39) |
MAOB-I | 462 (28) | 311 (29) | 151 (25) | 409 (28) | 36 (23) | 16 (36) |
COMT Inh | 86 (5) | 58 (5) | 28 (5) | 73 (5) | 9 (6) | 4 (9) |
Anticholinergic | 31 (2) | 23 (2) | 8 (1) | 26 (2) | 5 (3) | 0 (0) |
Amantadine | 327 (20) | 201 (19) | 126 (21) | 288 (20) | 27 (17) | 11 (25) |
A2A Ant | 10 (1) | 8 (1) | 2 (<1) | 9 (1) | 0 (0) | 1 (2) |
AChEI | 159 (10) | 127 (12) | 32 (5) | 136 (9) | 22 (14) | 1 (2) |
Antipsychotic | 86 (5) | 51 (5) | 35 (6) | 73 (5) | 11 (7) | 2 (5) |
